SRPT insider transaction filings
Sarepta Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-29. Screen SRPT transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-29 | 4 | SEVERINO MICHAEL — Chief Executive Officer, Director | Grant/award (A): 756,104 · Grant/award (A): 2,224,342 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Chambers Michael Andrew — Director | Grant/award (A): 16,875 | EDGAR |
| 2026-06-05 | 4 | Mayo Stephen — Director | Grant/award (A): 16,875 | EDGAR |
| 2026-06-05 | 4 | Boor Kathryn Jean — Director | Grant/award (A): 16,875 | EDGAR |
| 2026-06-05 | 4 | Nicaise Claude — Director | Grant/award (A): 16,875 | EDGAR |
| 2026-06-05 | 4 | Barry Richard — Director | Grant/award (A): 16,875 | EDGAR |
| 2026-06-05 | 4 | Wigzell Hans Lennart Rudolf — Director | Grant/award (A): 16,875 | EDGAR |
| 2026-06-05 | 4 | Connelly Deirdre P — Director | Grant/award (A): 16,875 | EDGAR |
| 2026-06-05 | 4 | BEHRENS M KATHLEEN — Director | Grant/award (A): 16,875 | EDGAR |
| 2026-03-13 | 4 | Wong Ryan Ho-Yan — Chief Financial Officer | Tax withholding (F): 256 @ $17.03 | EDGAR |
| 2026-03-13 | 4 | Rothfuss Cristin — EVP, General Counsel | Tax withholding (F): 974 @ $17.03 | EDGAR |
| 2026-03-13 | 4 | Mayo Stephen — Director | Sale (S): 7,239 @ $17.02 | EDGAR |
| 2026-03-13 | 4 | Estepan Ian Michael — Chief Operating Officer | Tax withholding (F): 1,097 @ $17.03 | EDGAR |
| 2026-03-13 | 4 | Rodino-Klapac Louise — President, R&D and Tech Ops | Tax withholding (F): 948 @ $17.03 | EDGAR |
| 2026-03-11 | 4 | Wong Ryan Ho-Yan — Chief Financial Officer | Tax withholding (F): 162 @ $16.95 · Tax withholding (F): 113 @ $16.95 | EDGAR |
| 2026-03-11 | 4 | Rothfuss Cristin — EVP, General Counsel | Tax withholding (F): 484 @ $16.95 · Tax withholding (F): 346 @ $16.95 | EDGAR |
| 2026-03-11 | 4 | Estepan Ian Michael — Chief Operating Officer | Tax withholding (F): 1,036 @ $16.95 · Tax withholding (F): 583 @ $16.95 | EDGAR |
| 2026-03-11 | 4 | Rodino-Klapac Louise — President, R&D and Tech Ops | Tax withholding (F): 504 @ $16.95 · Tax withholding (F): 895 @ $16.95 | EDGAR |
| 2026-03-03 | 4 | Wong Ryan Ho-Yan — Chief Financial Officer | Tax withholding (F): 450 @ $16.20 | EDGAR |
| 2026-03-03 | 4 | Rothfuss Cristin — EVP, General Counsel | Tax withholding (F): 408 @ $16.20 | EDGAR |
| 2026-03-03 | 4 | Estepan Ian Michael — Chief Operating Officer | Option exercise (M): 8,125 · Tax withholding (F): 3,301 @ $16.20 · Tax withholding (F): 875 @ $16.20 · Option exercise (M): 8,125 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Rodino-Klapac Louise — President, R&D and Tech Ops | Option exercise (M): 8,125 · Tax withholding (F): 3,718 @ $16.20 · Tax withholding (F): 767 @ $16.20 · Option exercise (M): 8,125 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Estepan Ian Michael — Chief Operating Officer | Option exercise (M): 2,069 @ $13.71 · Option exercise (M): 5,381 @ $13.71 · Option exercise (M): 2,069 (derivative) @ $0 · Option exercise (M): 5,381 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | Estepan Ian Michael — Chief Operating Officer | Grant/award (A): 1,875 (derivative) | EDGAR |
| 2026-02-27 | 4 | Rodino-Klapac Louise — President, R&D and Tech Ops | Grant/award (A): 1,875 (derivative) | EDGAR |
| 2026-01-29 | 4 | Nicaise Claude — Director | Option exercise (M): 10,500 @ $13.71 · Tax withholding (F): 6,780 @ $21.23 · Option exercise (M): 10,500 (derivative) @ $0 | EDGAR |
| 2026-01-29 | 4 | BEHRENS M KATHLEEN — Director | Option exercise (M): 10,500 @ $13.71 · Tax withholding (F): 6,494 @ $22.17 · Option exercise (M): 10,500 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Chambers Michael Andrew — Director | Disposition to issuer (D) · Grant/award (A) | EDGAR |
| 2025-12-18 | 4 | Estepan Ian Michael — Chief Operating Officer | Sale (S): 13,187 @ $22.31 | EDGAR |
| 2025-12-10 | 4 | Wong Ryan Ho-Yan — Chief Financial Officer | Tax withholding (F): 80 @ $20.96 · Tax withholding (F): 78 @ $20.96 | EDGAR |
| 2025-12-09 | 4 | INGRAM DOUGLAS S — Chief Executive Officer, Director | Grant/award (A): 50,000 @ $0 · Grant/award (A): 50,000 @ $0 · Grant/award (A): 73,001 @ $0 · Grant/award (A): 96,541 @ $0 · Grant/award (A): 269,542 @ $0 | EDGAR |
| 2025-12-02 | 4 | Rothfuss Cristin — EVP, General Counsel | Tax withholding (F): 229 @ $21.12 | EDGAR |
| 2025-11-19 | 4 | Rodino-Klapac Louise — President, R&D and Tech Ops | Tax withholding (F): 4,582 @ $18.42 | EDGAR |
| 2025-09-05 | 4 | Wong Ryan Ho-Yan — Chief Financial Officer | Grant/award (A): 93,875 @ $0 · Grant/award (A): 25,000 @ $0 | EDGAR |
| 2025-09-05 | 4 | Rothfuss Cristin — EVP, General Counsel | Grant/award (A): 93,875 @ $0 · Grant/award (A): 25,000 @ $0 | EDGAR |
| 2025-09-05 | 4 | Estepan Ian Michael — Chief Operating Officer | Grant/award (A): 93,875 @ $0 · Grant/award (A): 50,000 @ $0 | EDGAR |
| 2025-09-05 | 4 | Rodino-Klapac Louise — President, R&D and Tech Ops | Grant/award (A): 93,875 @ $0 · Grant/award (A): 50,000 @ $0 | EDGAR |
| 2025-08-06 | 4 | Arif Bilal — Chief Tech Ops Officer | Grant/award (A): 6,250 (derivative) @ $0 | EDGAR |
| 2025-08-06 | 4 | Estepan Ian Michael — Chief Operating Officer | Grant/award (A): 6,250 (derivative) @ $0 | EDGAR |
| 2025-08-06 | 4 | Rodino-Klapac Louise — President, R&D and Tech Ops | Grant/award (A): 6,250 (derivative) @ $0 | EDGAR |
| 2025-08-04 | 4 | Wong Ryan Ho-Yan — Chief Financial Officer | Tax withholding (F): 327 @ $16.42 | EDGAR |
| 2025-05-19 | 4 | Barry Richard — Director | Option exercise (M): 12,350 @ $32.63 · Option exercise (M): 12,350 (derivative) @ $0 | EDGAR |
| 2025-05-15 | 4 | Barry Richard — Director | Option exercise (M): 9,746 @ $25.18 · Option exercise (M): 10,500 @ $13.71 · Option exercise (M): 9,746 (derivative) @ $0 · Option exercise (M): 10,500 (derivative) @ $0 | EDGAR |
| 2025-03-13 | 4 | Nicaise Claude — Director | Option exercise (M): 9,746 @ $25.18 · Sale (S): 2,491 @ $99.64 · Option exercise (M): 9,746 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Rothfuss Cristin — EVP, General Counsel | Tax withholding (F): 491 @ $100.13 · Grant/award (A): 8,276 · Grant/award (A): 16,644 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Murray Dallan — Chief Customer Officer | Option exercise (M): 5,500 · Tax withholding (F): 996 @ $100.13 · Tax withholding (F): 2,737 @ $100.13 · Grant/award (A): 8,276 · Option exercise (M): 5,500 (derivative) @ $0 · Grant/award (A): 16,644 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Arif Bilal — Chief Tech Ops Officer | Tax withholding (F): 523 @ $100.13 · Grant/award (A): 8,276 · Grant/award (A): 16,644 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Chambers Michael Andrew — Director | Grant/award (A): 2,383 · Grant/award (A): 4,792 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Mayo Stephen — Director | Grant/award (A): 2,383 · Grant/award (A): 4,792 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Estepan Ian Michael — Chief Financial Officer | Option exercise (M): 5,500 · Tax withholding (F): 1,051 @ $100.13 · Tax withholding (F): 2,890 @ $100.13 · Grant/award (A): 8,276 · Option exercise (M): 5,500 (derivative) @ $0 · Grant/award (A): 16,644 (derivative) @ $0 | EDGAR |
Recent 8-K events — Sarepta Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-27 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-25 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-02-25 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-19 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-11 | 8-K | 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-08 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SRPT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →